Lauren White's most recent trade in C4 Therapeutics Inc was a trade of 2,250 Performance Restricted Stock Units done . Disclosure was reported to the exchange on Aug. 30, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 16,500 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Aug 2023 | 2,250 | 33,347 | - | - | Common Stock | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.93 per share. | 30 Aug 2023 | 661 | 32,686 | - | 2.9 | 1,937 | Common Stock |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 125,000 | 125,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 26,000 | 31,097 | - | 0 | Common Stock | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 6,398 | - | - | Common Stock | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 3,750 | 18,750 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.78 per share. | 30 Jan 2023 | 1,301 | 5,097 | - | 7.8 | 10,122 | Common Stock |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.01 per share. | 26 May 2022 | 1,102 | 2,648 | - | 7.0 | 7,725 | Common Stock |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 26,250 | 26,250 | - | - | Performance Restricted Stock Units | |
| C4 Therapeutics Inc | Lauren White | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2021 | 136,000 | 136,000 | - | - | Stock Option (Right to Buy) |